Under the agreement, Mankind Pharma will have the exclusive rights to register, import, market, sell, and distribute Sintilimab in India. Credit: Piotr Swat/Shutterstock. Mankind Pharma has entered ...

A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP inhibitors.

RioDerm-002 is under clinical development by Rion and currently in Phase I for Radiation Injury. According to GlobalData, Phase I drugs for Radiation Injury does not have sufficient historical data to ...

Trientine hydrochloride is under clinical development by Innolife and currently in Phase II for Systolic Heart Failure. According to GlobalData, Phase II drugs for Systolic Heart Failure have a 67% ...

AstraZeneca and Daiichi Sankyo have withdrawn marketing authorisation application in the EU voluntarily, intended for datopotamab deruxtecan.

CSTI-500 is under clinical development by ConSynance Therapeutics and currently in Phase I for Prader-Willi Syndrome (PWS).

COYA-301 is under clinical development by Coya Therapeutics and currently in Phase II for Alzheimer's Disease.

Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Metastatic Colorectal Cancer.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Marginal Zone B-cell Lymphoma.

Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Diffuse Large B-Cell Lymphoma.

EXO-CD24 is under clinical development by Nano24med and currently in Phase II for Acute Respiratory Distress Syndrome.